quant Mutual FundEquity Scheme - Mid Cap Fund13.8 years
The scheme aims at providing long term capital appreciation and generating income with a diversified portfolio of Mid Cap companies.
Buying brief
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 30 Oct 2026
Stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
In three lines
Fits if · Risk-adjusted return sits above the documented risk-free proxy.
Prefer peers if · Prefer Baroda BNP Paribas Mid Cap Fund if you want a same-category peer with stronger evidence.
Buy checklist
History depth
Pass
13.8 years of path to read.
Engine status
Watch
Recent evidence is mixed. Compare peers before increasing exposure.
Expense ratio
Pass
1.21% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Pass
Peak-to-trough -33.4%. Ask whether you can hold through a similar fall.
Vs category
Watch
55% of rolling 3Y windows beat the category median, same plan and option.
Manager tenure
Watch
Sameer Kate · 1.7 years on the scheme.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Watch
Top 10 holdings ≈ 66.5% of the portfolio.
Same-category peers are preloaded into compare when available.
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 33%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
Monitor is recent mixed evidence - keep the SIP unless the buying brief says prefer peers, then swap with intent.
NAV
Path not in current snapshots
n/a
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
SIP XIRR
Equal monthly instalments to latest NAV
Date-aligned against NIFTY MIDCAP 150 TRI. Capture ratios use common month-end observations through 30 Oct 2026.
Peak to trough from a running NAV high, with the path and recovery episodes.
Drawdown
Path not in current snapshots
n/a
29 Jan 2020 – 3 Aug 2020
Trough 23 Mar 2020 · recovered in 133 days
-33.4%
15 Jul 2024 – open
Trough 4 Mar 2025 · not recovered
-26.0%
31 Aug 2018 – 29 Jan 2020
Trough 22 Aug 2019 · recovered in 160 days
-19.5%
11 Apr 2022 – 5 Sept 2022
Trough 20 Jun 2022 · recovered in 77 days
-18.5%
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
18
Vs category
55
Consistency
51
Risk-adjusted
59
Drawdown
16
Mean
40
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Buying stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
Why this status
Supporting reads
31 Aug 2026 · 43 holdings · top 10 are 66.5%.
Aurobindo Pharma Ltd
Healthcare
10.4%
Tata Communications Ltd
Technology
8.4%
Lloyds Metals and Energy Ltd
Materials
8.2%
Repo
Unspecified
7.8%
IRB Infrastructure Developers Ltd
Industrials
6.0%
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
24 Sept 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
23 Sept 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
22 Sept 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
21 Sept 2026
DECISION
Status moved from REVIEW to MONITOR.
18 Sept 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
18 Sept 2026
Same-category peers with enough history to inspect beside this fund - including tradeoffs.
Baroda BNP Paribas Mutual Fund
ITI Mutual Fund
Caveat: Higher volatility
Union Mutual Fund
Caveat: Higher volatility
Axis Mutual Fund
LIC Mutual Fund
Caveat: Higher volatility · Higher TER
quant Mutual FundEquity Scheme - Mid Cap Fund13.8 years
The scheme aims at providing long term capital appreciation and generating income with a diversified portfolio of Mid Cap companies.
Buying brief
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 30 Oct 2026
Stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
In three lines
Fits if · Risk-adjusted return sits above the documented risk-free proxy.
Prefer peers if · Prefer Baroda BNP Paribas Mid Cap Fund if you want a same-category peer with stronger evidence.
Buy checklist
History depth
Pass
13.8 years of path to read.
Engine status
Watch
Recent evidence is mixed. Compare peers before increasing exposure.
Expense ratio
Pass
1.21% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Pass
Peak-to-trough -33.4%. Ask whether you can hold through a similar fall.
Vs category
Watch
55% of rolling 3Y windows beat the category median, same plan and option.
Manager tenure
Watch
Sameer Kate · 1.7 years on the scheme.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Watch
Top 10 holdings ≈ 66.5% of the portfolio.
Same-category peers are preloaded into compare when available.
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 33%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
Monitor is recent mixed evidence - keep the SIP unless the buying brief says prefer peers, then swap with intent.
NAV
30 Oct 2026 · -2.2% over 1Y
236.1921
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
SIP XIRR
Equal monthly instalments to latest NAV
Date-aligned against NIFTY MIDCAP 150 TRI. Capture ratios use common month-end observations through 30 Oct 2026.
Peak to trough from a running NAV high, with the path and recovery episodes.
Drawdown
30 Oct 2026
-16.0%
29 Jan 2020 – 3 Aug 2020
Trough 23 Mar 2020 · recovered in 133 days
-33.4%
15 Jul 2024 – open
Trough 4 Mar 2025 · not recovered
-26.0%
31 Aug 2018 – 29 Jan 2020
Trough 22 Aug 2019 · recovered in 160 days
-19.5%
11 Apr 2022 – 5 Sept 2022
Trough 20 Jun 2022 · recovered in 77 days
-18.5%
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
18
Vs category
55
Consistency
51
Risk-adjusted
59
Drawdown
16
Mean
40
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Buying stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
Why this status
Supporting reads
31 Aug 2026 · 43 holdings · top 10 are 66.5%.
Aurobindo Pharma Ltd
Healthcare
10.4%
Tata Communications Ltd
Technology
8.4%
Lloyds Metals and Energy Ltd
Materials
8.2%
Repo
Unspecified
7.8%
IRB Infrastructure Developers Ltd
Industrials
6.0%
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
24 Sept 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
23 Sept 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
22 Sept 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
21 Sept 2026
DECISION
Status moved from REVIEW to MONITOR.
18 Sept 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
18 Sept 2026